

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Effects of cholecalciferol supplementation on Bone mineral metabolism in end stage renal disease patients in comparison with placebo

Protocol summary

Summary

Abstract INTRODUCTION There is a great interest in vitamin-D supplementation that has recently grown; as the scientific community has reported extra renal production of calcitriol by cells in nearly all body systems and the presence of vitamin-D binding receptors in different tissues⁵ as the 1- α hydroxylase enzyme has been found in parts of the body outside the kidney¹. A recent study in hemodialysis patients showed that 1,25-dihydroxyvitamin-D₃ levels increased after supplementation with nutritional vitamin-D, suggesting that even in ESRD there is enough extra renal 1- α hydroxylase activity to influence serum levels there by showing a role for nutritional vitamin D in patients with kidney disease⁶ **OBJECTIVES** 1. To find the effect of oral cholecalciferol supplementation on Bone Mineral Metabolism (25 hydroxyvitamin D level, Alkaline Phosphatase, intact Parathyroid Hormone (iPTH), Calcium (Ca), Phosphorus (P), calcium phosphorus product(Ca x P)) and 2. To find the effects of its supplementation on marker of inflammation (C Reactive Protein, White blood cell count) and chronic musculoskeletal symptoms (visual analog scale). **MATERIAL AND METHODS:** Study Design: Double blind Randomized controlled trail. Settings: The study will be carried out in the Hemodialysis Unit, Shaikh Zayad Hospital Lahore. Duration of Study: 2 months. **SAMPLE SIZE:** 70 , 35 in each group The sample size of 35 was estimated by using 95% confidence level, 90% power of the test with expected iPTH level at baseline and at two months 295 ± 90 and 249 ± 80 respectively²⁴. **SAMPLING TECHNIQUE:** Lottery method **SAMPLE SELECTION:** Inclusion criteria Age more than 18 years On hemodialysis thrice per week for more than 3 months Both the gender Patients who give informed consents Exclusion criteria The patients with history of active bleeding (melena, hematemesis, hematochezia). Patients who have taken cholecalciferol or ergocalciferol within two months period, Patients taking cinacalcet Iv Iron in 1 month prior to enrollment

Blood transfusion 1 month prior to enrollment during the study Any diagnosed malignancy, tubercular infection, sarcoidosis, pregnancy Calcitriol or activated Vitamin D₃ or erythropoietin dosage adjustment 1 month prior to enrollment Patients having corrected serum calcium >10.2 mg/dl or having serum phosphorus >6mg/dl **OUTCOME VARIABLES** Serum level of 25 hydroxyvitamin D level, Alkaline Phosphatase, intact Parathyroid Hormone (iPTH), Calcium (Ca), Phosphorus (P), calcium phosphorus product(Ca x P) C Reactive Protein, White blood cell count) and for Chronic musculoskeletal symptoms (visual analog scale).

General information

Acronym

ESRD-end stage renal disease

IRCT registration information

IRCT registration number: **IRCT2015091323989N1**

Registration date: **2015-11-09, 1394/08/18**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2015-11-09, 1394/08/18

Registrant information

Name

Sumit Acharya

Name of organization / entity

College of physician and surgeon of pakistan

Country

Pakistan

Phone

04299231320

Email address

med-2009-5529@csp.edu.pk

Recruitment status

Recruitment complete

Funding source
Department of Nephrology, Shaikh Zayad Hospital

Expected recruitment start date

2015-11-10, 1394/08/19

Expected recruitment end date

2015-12-10, 1394/09/19

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effects of cholecalciferol supplementation on Bone mineral metabolism in end stage renal disease patients in comparison with placebo

Public title

Effect of Vitamin D (Cholecalciferol) supplementation on bone mineral metabolism in patient on Dialysis

Purpose

Supportive

Inclusion/Exclusion criteria

Inclusion criteria: Age more than 18 years On hemodialysis thrice per week for more than 3 months Both the gender Patients who give informed consents
Exclusion criteria: The patients with history of active bleeding (melena, hematemesis, hematochezia). Patients who have taken cholecalciferol or ergocalciferol within two months period, Patients taking cinacalcet Iv Iron in 1 month prior to enrollment Blood transfusion 1month prior to enrollment during the study Any diagnosed malignancy, tubercular infection, sarcoidosis, pregnancy Calcitriol or active vitamin D3 or erythropoietin dosage adjustment 1 month prior to enrollment Patients having corrected serum calcium>10.2 mg/dl or having serum phosphorus >6mg/dl

Age

From **18 years** old to **70 years** old

Gender

Both

Phase

4

Groups that have been masked

No information

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Group A and Group B will be written in 70 close envelop,

35 each . Hemodialysis staff will take the envelop out by lottery method and allocate the group.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Dr Farkandha, National Health council, Institutional Review Board, IORG0006065, Federal postgraduate

Street address

National Health Research Complex, Federal Postgraduate Medical Institute, Shaikh Zayad Hospital, Muslim Town

City

Lahore

Postal code

0092

Approval date

2015-02-11, 1393/11/22

Ethics committee reference number

1361

Health conditions studied

1

Description of health condition studied

End stage renal disease patients on hemodialysis

ICD-10 code

N18.5

ICD-10 code description

End stage kidney disease: on dialysis

Primary outcomes

1

Description

1. 25 hydroxyvitamin D level

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

ELISA kit

2

Description

2. intact Parathyroid Hormone (iPTH)

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

ELISA kit

3

Description

3. Alkaline Phosphatase

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

Standard chemical analyzer

4

Description

4. Calcium (Ca)

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

Standard chemical analyzer

5

Description

5. Phosphorus (P)

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

Standard chemical analyzer

6

Description

6. calcium phosphorus product(Ca x P)

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

calculated from calcium and phosphorus product

Secondary outcomes

1

Description

1. C Reactive Protein

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

ELISA Kit

2

Description

2. Chronic musculoskeletal symptoms

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

Visual Analog Scale

3

Description

3. White blood cell count

Timepoint

At baseline and 2 months after the date of intervention

Method of measurement

Automated counter

Intervention groups

1

Description

Intervention /group A Supplementation with cholecalciferol will be done in 25 hydroxyvitamin D deficiency 35 patients on thrice weekly maintenance hemodialysis patients according to 25-hydroxyvitamin D3 serum levels. 50,000 IU cholecalciferol once a week will be given for patients with 25-hydroxyvitamin D levels <15 ng/ml, 10,000 IU once a week when 25-hydroxyvitamin D3 level between 16 and 30 ng/ml. The supplementation with cholecalciferol capsule, once a week will be given orally, with meal during their hemodialysis session, under supervision by study staff. All the test 25-hydroxyvitamin D3 level, iPTH, alkaline phosphatase, Ca, P, albumin, Complete blood count, and CRP level will be done before intervention and repeated after two months of supplementation.

Category

Treatment - Drugs

2

Description

Control group/Group B Similar placebo is given to group B patients on thrice weekly maintenance hemodialysis patients according to 25-hydroxyvitamin D levels . The supplementation with placebo, once a week will be given orally, with meal during their hemodialysis session, under supervision by study staff. All the test 25-hydroxyvitamin D3 level, iPTH, alkaline phosphatase, Ca, P, albumin, Complete blood count, and CRP level will be done before the intervention and repeated after two months of supplementation.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Nephrology Department, Shaikh Zayad Hospital

Full name of responsible person

Prof Waqar Ahmed

Street address

Shaikh Zayad Hospital, Nephrology Department, Khayaban-e-jamia punjab road, Block D New Muslim Town

City

Lahore

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Nephrology Department, Shaikh Zayad Hospital

Full name of responsible person

Prof Waqar Ahmed

Street address

Khayaban-e-jamia punjab road, Block D New Muslim Town

City

Lahore

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Nephrology Department, Shaikh Zayad Hospital

Proportion provided by this source**Public or private sector***empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***2****Sponsor****Name of organization / entity**

Shaikh Zayad Hospital

Full name of responsible person

Prof Dr Farrukh Iqbal

Street address

Khayaban-e-jamia punjab road, Block D New Muslim Town

City

Lahore

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shaikh Zayad Hospital

Proportion provided by this source**Public or private sector***empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

College of Physician and Surgeon of Pakistan

Full name of responsible person

Sumit Acharya

Position

FCPS Nephrology

Other areas of specialty/work**Street address**

Shaikh Zayad Hospital, Nephrology Department, Khayaban-e-jamia punjab road, Block D New Muslim Town

City

Lahore

Province

Punjab

Postal code

92

Phone

00924299230727

Fax**Email**

med-2009-5529@cpsp.pk

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

College of Physician and Surgeon of Pakistan

Full name of responsible person

Sumit Acharya

Position

FCPS Nephrology

Other areas of specialty/work**Street address**

Shaikh Zayad Hospital, Nephrology Department, Khayaban-e-jamia punjab road, Block D New Muslim Town

City

Lahore

Province

Punjab

Postal code

0092

Phone

00924299230727

Fax**Email**

sumitacharya2@gmail.com

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

College of Physician and Surgeon of Pakistan

Full name of responsible person

Sumit Acharya

Position

FCPS Nephrology

Other areas of specialty/work**Street address**

Shaikh Zayad Hospital, Nephrology Department, Khayaban-e-jamia punjab road, Block D New Muslim Town,

City

Lahore

Province

Punjab

Postal code

0092

Phone

00

Fax**Email**

sumitacharya2@gmail.com

Web page address**Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*